Valuation : GI Dynamics, Inc.

Market Cap 440K 379K 357K 326K 609K 41.59M 611K 4.21M 1.64M 21.34M 1.65M 1.62M 68.74M P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 3.28M 2.82M 2.66M 2.43M 4.54M 310M 4.55M 31.37M 12.17M 159M 12.31M 12.05M 512M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 05/08/2025
Director of Finance/CFO 57 01/08/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member - 20/10/2020
Director/Board Member - -
Director/Board Member 69 01/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
28/1/21 Free

Chairman

1,384,483 0.4875%
28/1/21 Free

Chief Executive Officer

11,075,869 3.8998%

Financials

2019 2020
Net sales - -
Net income -17.33M -14.92M -14.03M -12.82M -23.98M -1.64B -24.05M -166M -64.35M -840M -65.09M -63.67M -2.7B -11.14M -9.58M -9.02M -8.24M -15.41M -1.05B -15.45M -107M -41.34M -539M -41.82M -40.9M -1.74B
Net Debt 2.89M 2.48M 2.34M 2.14M 3.99M 273M 4.01M 27.62M 10.72M 140M 10.84M 10.6M 451M 2.84M 2.44M 2.3M 2.1M 3.93M 268M 3.94M 27.16M 10.54M 138M 10.66M 10.43M 443M
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. GIDYL Stock